Inc. (NASDAQ:ETNB), with a market capitalization of $1.14 billion, is a clinical-stage biopharmaceutical company focusing on the development of innovative therapies for the treatment of liver and ...

Pegozafermin. It has two Phase 3 trials: one for MASH and the other for SHTG. See why I continue to rate ETNB stock a buy.

(NASDAQ: ETNB) couldn't quite keep pace with the broader stock market on Tuesday. Investors were hesitant to buy shares of ...

BofA Securities has recently resumed 89bio Inc (ETNB) stock to Buy rating, as announced on April 22, 2024, according to Finviz. Earlier, on January 12, 2024, RBC Capital Mkts had reduced the stock ...

SAN FRANCISCO, Jan. 28, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on ...

Inc. (NASDAQ:ETNB – Get Free Report) has received an average recommendation of “Moderate Buy” from the seven analysts that ...

Goldman Sachs, Leerink and BofA acted as joint book running managers for the offering.Invest with Confidence: Follow TipRanks' Top Wall Street ...

It was the best of biotech times, it was the worst of biotech times: One company soars, another stumbles and a third outlines ...

Inc. (NASDAQ:ETNB – Get Free Report) was the recipient of some unusual options trading on Monday. Traders acquired 2,228 call options on the company. This is an increase of 346% compared to the ...

Akero Therapeutics (AKRO) stock was upgraded by Bank of America based on Phase 2 data the company shared for its liver disorder drug, efruxifermin. Read more here.

89bio, Inc. has announced the launch of an underwritten public offering for $250 million in common stock, with the option for some investors to purchase pre-funded warrants instead. The company ...

BioAge scrapped the drug at the center of its $198 million initial public offering last year. Elsewhere, Akero and 89bio raised $600 million combined and Allakos laid off staff.